Top

Published in:

01-02-2007 | Clinical–Patient Studies

Prognostic factors for anaplastic astrocytomas

Authors: Alessia Compostella, Alicia Tosoni, Valeria Blatt, Enrico Franceschi, Alba A. Brandes

Published in: Journal of Neuro-Oncology | Issue 3/2007

Abstract

Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas. Definitive data on predictive and prognostic factors are lacking for these neoplasms that are considered the most enigmatic entity among the whole spectrum of astrocytic tumors because of their unclear biologic behavior and variable clinical outcome. Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status. Attempts have been made to identify biological prognostic factors for response to therapy and clinical outcome, as well as potential targets for new therapies. Potential prognostic biomarkers concern tumor suppressor genes on chromosome 9q that are involved in the RB1 pathway; PTEN, the PI3k/Akt/p70s6k cascade, survivin gene, Formylpeptide receptor, minichromosome maintenance protein 3 and genes on chromosome 7. Furthermore, some angiogenic factors (e.g. hypoxia-inducible factor-1α, vascular endothelial growth factor and scatter factor/hepatocyte growth factor) and the methylation status of O6-methylguanine-DNA methyltransferase gene (one of the main effectors of DNA repair system) are emerging novel putative determinants of prognosis. Moreover, recent studies on magnetic resonance imaging characteristics give prognostic significance to the presence of necrosis and enhancement. The state of the art pictured here underlie the recent interest on gene expression profile to identify aberrations useful to understand the biologic behavior of astrocytic tumors. Our knowledge in this field is still limited, and remains an issue of great concern.

Silverberg E, Boring CC, Squires TS (1990) Cancer statistics, 1990. CA Cancer J Clin 40:9–26PubMed

Kleihues P, Cavenee WK (2000) World Health Classification of Tumors. Tumors of the nervous system. Pathology and Genetics. IARC Scientific Publications, Lyon

Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786PubMed

Vertosick FT Jr, Selker RG, Arena VC (1991) Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28:496–501PubMedCrossRef

McCormack BM, Miller DC, Budzilovich GN et al (1992) Treatment and survival of low-grade astrocytoma in adults—1977–1988. Neurosurgery 31:636–642; discussion 642PubMedCrossRef

Daumas-Duport C, Scheithauer B, O’Fallon J et al (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165PubMedCrossRef

Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225; discussion 226–219PubMed

Perry A, Jenkins RB, O’Fallon JR et al (1999) Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 86:672–683PubMedCrossRef

Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071PubMedCrossRef

10.

Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRef

11.

Kunwar S, Mohapatra G, Bollen A et al (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683–7688PubMed

12.

Schwartz SA, Weil RJ, Thompson RC et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65:7674–7681PubMed

13.

Sallinen PK, Sallinen SL, Helen PT et al (2000) Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumors in the context of the WHO 1979 and WHO 1993 grading schemes. Neuropathol Appl Neurobiol 26:319–331PubMedCrossRef

14.

Burger PC, Vogel FS, Green SB et al (1985) Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56:1106–1111

15.

Barker FG, II, Davis RL, Chang SM et al (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77:1161–1166PubMedCrossRef

16.

Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474PubMed

17.

Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol 58:203–215PubMedCrossRef

18.

Backlund LM, Nilsson BR, Goike HM et al (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9:4151–4158PubMed

19.

Backlund LM, Nilsson BR, Liu L et al (2005) Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 93:124–130PubMedCrossRef

20.

Albarosa R, Colombo BM, Roz L et al (1996) Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet 58:1260–1267PubMed

21.

Rasheed BK, McLendon RE, Friedman HS et al (1995) Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10:2243–2246PubMed

22.

Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947PubMedCrossRef

23.

Steck PA, Pershouse MA, Jasser SA et al (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362PubMedCrossRef

24.

Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256PubMedCrossRef

25.

Chakravarti A, Zhai G, Suzuki Y et al. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926–1933PubMedCrossRef

26.

Chakravarti A, Noll E, Black PM et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063–1068PubMedCrossRef

27.

Zhen HN, Zhang X, Hu PZ et al (2005) Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775–2783PubMedCrossRef

28.

Jensen RL, Ragel BT, Whang K et al (2006) Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol (in press)

29.

Korkolopoulou P, Patsouris E, Konstantinidou AE et al (2004) Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30:267–278PubMedCrossRef

30.

Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neurooncol 7:436–451

31.

Zhou Y, Bian X, Le Y et al (2005) Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 97:823–835PubMedCrossRef

32.

El-Rayes BF, Norton CS, Sakr W et al (2005) Cellular DNA content parameters as prognostic indicators in human astrocytomas. J Neurooncol 71:85–89PubMedCrossRef

33.

Sallinen PK, Haapasalo HK, Visakorpi T et al (1994) Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275–282PubMedCrossRef

34.

Reavey-Cantwell JF, Haroun RI, Zahurak M et al (2001) The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 55:195–204PubMedCrossRef

35.

Mohapatra G, Kim DH, Feuerstein BG (1995) Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer 13:86–93PubMedCrossRef

36.

Mohapatra G, Bollen AW, Kim DH et al (1998) Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer 21:195–206PubMedCrossRef

37.

Weber RG, Sabel M, Reifenberger J et al (1996) Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 13:983–994PubMed

38.

Schlegel J, Scherthan H, Arens N et al (1996) Detection of complex genetic alterations in human glioblastoma multiforme using comparative genomic hybridization. J Neuropathol Exp Neurol 55:81–87PubMedCrossRef

39.

Harada K, Nishizaki T, Ozaki S et al. (1998) Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res 58:4694–4700PubMed

40.

Nishizaki T, Ozaki S, Harada K et al (1998) Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 21:340–346PubMedCrossRef

41.

Chumbalkar VC, Subhashini C, Dhople VM et al (2005) Differential protein expression in human gliomas and molecular insights. Proteomics 5:1167–1177PubMedCrossRef

42.

Soling A, Sackewitz M, Volkmar M et al (2005) Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res 11:249–258PubMed

43.

Kamiryo T, Tada K, Shiraishi S et al (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349–357; discussion 357PubMedCrossRef

44.

Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354PubMedCrossRef

45.

Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874PubMedCrossRef

46.

Balana C, Ramirez JL, Taron M et al (2003) O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9:1461–1468PubMed

47.

Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938PubMedCrossRef

48.

Blanc JL, Wager M, Guilhot J et al (2004) Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68:275–283PubMedCrossRef

49.

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

50.

Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174PubMedCrossRef

51.

Nutt CL, Mani DR, Betensky RA et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607PubMed

52.

Freije WA, Castro-Vargas FE, Fang Z et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503–6510PubMedCrossRef

53.

Pronin IN, Holodny AI, Petraikin AV (1997) MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema. Neuroradiology 39:348–350PubMedCrossRef

54.

Hamstra DA, Chenevert TL, Moffat BA et al (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102:16759–16764PubMedCrossRef

55.

Bergsland EK (2006) When does the presence of the target predict response to the targeted agent? J Clin Oncol 24:213–216PubMedCrossRef

Title: Prognostic factors for anaplastic astrocytomas
Authors: Alessia Compostella
Alicia Tosoni
Valeria Blatt
Enrico Franceschi
Alba A. Brandes
Publication date: 01-02-2007
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-006-9232-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prognostic factors for anaplastic astrocytomas

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2007

Clear cell Meningioma, an uncommon variant of meningioma: a clinicopathologic study of nine cases

PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium

Primary peripheral primitive neuroectodermal tumors of the spinal cord: report of two cases and review of the literature

EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofibromatosis type 1 patients

Functional compensation of the claustrum: lessons from low-grade glioma surgery

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme